Massive eye drug study reveals rare inflammation risk
NCT ID NCT06769412
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at over 550,000 people who received Eylea® injections for eye conditions to find out how often retinal vasculitis (a rare eye inflammation) occurs. Researchers used a large US registry and medical records to confirm cases. The goal was to better understand the safety of this common treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETIC MACULAR EDEMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Regeneron Research Site
Tarrytown, New York, 10591, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Longer-Lasting eye injection could cut treatment visits for macular disease
- Can a new eye injection preserve vision in south asians with diabetes?
- Could a biosimilar eye injection offer a new way to treat diabetic macular edema?
- Can a new eye injection save vision in wet AMD?
- Can a steroid implant boost the effect of standard eye injections for hard-to-treat diabetic macular edema?
- Eye injection aims to tame leading causes of blindness